Skip to main content

Advertisement

Figure 1 | BMC Psychiatry

Figure 1

From: Quetiapine fumarate augmentation for patients with a primary anxiety disorder or a mood disorder: a pilot study

Figure 1

For the present study, patients were randomized with a 2:1 probability of receiving either quetiapine (N = 26), or placebo(N = 13) for 8 weeks in order to minimize exposure to a single SSRI/SNRI alone(placebo-controlled group).A total of 35 eligible patients who used the study medication and had at least one follow-up evaluation were included in the intention-to treat (ITT) population. A total of 21 patients completed the study.

Back to article page